Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson

Size: px
Start display at page:

Download "Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson"

Transcription

1 DRTUMUMB, a CD38 Monoclonal ntibody Study in dvanced Multiple Myeloma an Open-Label, Dose Escalation Followed by Open-Label Extension in a Single-rm Phase I/II Study bstract #S576 Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson University Medical Center Utrecht, Netherlands; Vejle Hospital, Denmark; Rigshospitalet, Copenhagen, Denmark; Karolinska Institutet, Stockholm, Sweden; Genmab /S, Copenhagen, Denmark; Dana-Farber Cancer Institute, Boston, M, US

2 Disclosures Genmab: dvisory Board, research support Johnson & Johnson: dvisory Board Mundipharma: dvisory Board Celgene: Research support

3 Human CD38 mb with Broad-Spectrum Killing ctivity Human IgG1k monoclonal antibody Broad spectrum mechanisms of action including CDC, DCC, DCP, apoptosis induction and inhibition of enzymatic activity In development for multiple myeloma Here we present data from the dose-escalation (part 1) of the FIH study in patients with relapsed or relapsed and refractory multiple myeloma

4 Objectives Primary Establishment of the safety profile of daratumumab Secondary Daratumumab: GEN501 Phase I/II Study of Monotherapy in Relapsed or Relapsed and Refractory Multiple Myeloma To establish the pharmacokinetic profile of daratumumab Evaluation of the efficacy of daratumumab according to International Myeloma Workshop Consensus Panel 1, Blood 2011;117: (IMWG) Evaluation of the immunogenicity of daratumumab

5 Main Inclusion Criteria Patients with advanced Multiple Myeloma requiring systemic therapy Patients with relapsed or relapsed and refractory disease with at least 2 prior lines of therapy and without further established treatment options Patients with ECOG performance status 0-2 Patients having a life expectancy >3 months

6 Trial Design PRT 1 Doseescalation cohorts Open label, weekly i.v. infusion, 8 weeks Dose-escalation: 3+3 scheme mg/kg PRT 2 Expansion cohorts Ongoing Several cohorts and dose schedules are being tested - start with pre-dose at 10% of the full dose, max 10 mg - three weeks delay after first full dose - governed by independent data monitoring committee

7 Patient Characteristics (Part 1: N=32) Cohort No. of subjects ge a No. of prior treatments Refractory to Len and Bort Len/Thal b Bort b Dex/Steroid other b Chemo b,c uto/llo b 1 mg/kg (42-76) 5 (2-8) e 88% / 71% 100% 88% / 41% 100% 65% / 12% 2 mg/kg 3 64 (60-71) 8 (6-10) e 100% / 100% 100% 100% / 100% 100% 100% / 0% 4 mg/kg 3 64 (62-66) 3 d (3-8) 67% f 100% / 33% 100% 100% / 33% 100% 67% / 33% 8 mg/kg 3 60 (56-68) 8 d (6-12) 100% f 100% / 67% 100% 100% / 67% 100% 100% / 33% 16 mg/kg 3 55 (54-59) 4 d (4-5) 67% f 100% / 67% 100% 100% / 33% 100% 100% / 67% 24 mg/kg 3 58 (50-69) 6 d (4-6) 67% f 100% / 67% 100% 100% / 33% 100% 67% / 0% PRT mg/kg (50-69) 5.5 (3-12) 75% 100% / 58% 100% 100% / 42% 100% 83% / 33% llo: allogeneic stem cell transplantation, uto: autologous stem cell transplantation, Bort: bortezomib, Chemo: chemotherapy, Len: lenalidomide, No: number, Thal: thalidomide a: median (range), b: number of patients exposed to treatment, c: vincristine, doxorubicin, cyclophosphamide, melphalan and others, d: revised after additional data collection, e: data not collected, f: data collected retrospectively

8 Infusion Related dverse Events

9 SEs ssessed Related to Daratumumab Event Bronchospasm nemia Thrombocytopenia ST > 5.2 times upper limit of normal Cytokine release syndrome PRT 1 N=32 1 patient: grade 2 (2 mg/kg) (2 days later grade 3) 1 patient: grade 2 (24 mg/kg) 1 patient: grade 3 (0.1 mg/kg) (DLT) 1 patient: grade 4 (0.1 mg/kg) 1 patient: grade 2 + grade 3 (1.0 mg/kg) (DLT) 1 patient: grade 2 (0.1 mg/kg)

10 plasma conc ( g/ml) plasma conc ( g/ml) Daratumumab (Part 1) Plasma Concentration mg/kg 16 mg/kg 8 mg/kg 4 mg/kg mg/kg 1 mg/kg 0.5 mg/kg 1 LOQ time (days) time (days)

11 Relative change in paraprotein from baseline (%) Daratumumab Response (Part 1) Maximal Change in Paraprotein 100 < 1 mg/kg 2 mg/kg 4 mg/kg 8 mg/kg 16 mg/kg 24 mg/kg C C B C C B C B B C C Patient number : serum M-component, B: urine M-component, C: Free Light Chains (FLC)

12 (Part 1) Response according to IMWG

13 4mg/kg (Part 1) Summary of Response Cohort (mg/kg)v N Max. reduction in M-component (%) Serum Urine Max. reduction in difference between involved and uninvolved FLC (%) Max. reduction in plasma cells in bone marrow biopsy (%) [Baseline value (%)] Response according to IMWG a [12.5] 89 [23] 97 [19] MR PR PR [14] 93 [7.5] - SD MR NE [31.5] 100 [2] PD PR SD b b [18.5] 17 [3.0] 91 [17.0] PR MR PR no measurable disease/normal at Baseline, - data not available, a Evaluation based on max. reduction in M-component or FLC, b Follow up still ongoing

14 Progression-Free Survival

15 Conclusion 1/2 Daratumumab has shown a favorable safety profile as monotherapy in relapsed or relapsed and refractory Multiple Myeloma patients In part 1, where 15 of 32 (47%) heavily pre-treated evaluable Multiple Myeloma patients received 8 weeks of daratumumab as monotherapy in doses up to 24 mg/kg, a reduction in paraprotein was observed In 10 of these 32 patients (31%), this reduction qualified to a clinical response: 5 patients achieving PR (15.5%) 5 patients achieving MR (15.5%) In 8 of 12 patients (67%) at doses 4 mg/kg and above achieved a clinical response: 5 patients achieving PR (42%) 3 patients achieving MR (25%)

16 Conclusion 2/2 Biochemical response was accompanied by clearance of myeloma cells from the bone marrow t higher dose levels, observed plasma concentrations are close to those predicted Overall increased daratumumab exposure correlated with longer progression free survival Further studies: We are currently exploring an 8 mg/kg weekly schedule but will also explore other doses and different schedules

17 cknowledgments Special thanks to investigators, sub-investigators, research staff and patients and their families at the collaborating centers: Karolinska Institutet, Stockholm, Sweden Rigshospitalet, Copenhagen, Denmark University Medical Center Utrecht, Netherlands Vejle Hospital, Denmark Dana-Farber Cancer Institute, Boston M, US

DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY

DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY Torben Plesner, Henk Lokhorst, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson

More information

Daratumumab A human CD38 mab with broad-spectrum killing activity

Daratumumab A human CD38 mab with broad-spectrum killing activity Abstract #809 Daratumumab a CD38 mab for the Treatment of Relapsed /Refractory Multiple Myeloma Patients: Preliminary Efficacy Data from a Multicenter Phase I/II Study Torben Plesner, Vejle Hospital, Denmark;

More information

Dose-Dependent Efficacy of Daratumumab as Monotherapy in Patients with Relapsed or Refractory Multiple Myeloma

Dose-Dependent Efficacy of Daratumumab as Monotherapy in Patients with Relapsed or Refractory Multiple Myeloma Dose-Dependent Efficacy of Daratumumab as Monotherapy in Patients with Relapsed or Refractory Multiple Myeloma Henk Lokhorst, Jacob Laubach, Hareth Nahi, Torben Plesner, Peter Gimsing, Markus Hansson,

More information

Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands. 1

Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands. 1 Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503) Torben Plesner, MD,PhD

More information

Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands. 1

Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands. 1 Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503) Torben Plesner, MD,PhD

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with

More information

Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines

Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival

More information

Considerations for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients

Considerations for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients Hello, my name is Suzanne Lentzsch. I am an associate professor of medicine at Columbia University Medical Center in New York. I am the clinical director of the Multiple Myeloma Amyloidosis Service. Today,

More information

A Phase Ib Trial of Isatuximab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Interim Results From 2 New Dose Cohorts

A Phase Ib Trial of Isatuximab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Interim Results From 2 New Dose Cohorts A Phase Ib Trial of Isatuximab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Interim Results From 2 New Dose Cohorts Ravi Vij, 1 Nikoletta Lendvai, 2 Thomas Martin, 3 Rachid

More information

Background. Pomalidomide

Background. Pomalidomide A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide alone or in combination with low-dose Dexamethasone

More information

Please follow the link below to document your learning in MAINPORT:

Please follow the link below to document your learning in MAINPORT: Multiple Myeloma Guideline Knowledge Assessment - Program Read the guideline and answer the multiple choice questions below which are based on two hypothetical cases using evidence based approaches outlined

More information

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections

More information

Module 6 Multiple Myeloma: Relapsed/Refractory Disease Care Team Considerations. Learning Objectives

Module 6 Multiple Myeloma: Relapsed/Refractory Disease Care Team Considerations. Learning Objectives Module 6 Multiple Myeloma: Relapsed/Refractory Disease Care Team Considerations Learning Objectives 1. Define the characteristics of relapsed, refractory, as well as relapsed AND refractory myeloma 2.

More information

Multiple Myeloma How to Evaluate Response To Treatment and Relapse

Multiple Myeloma How to Evaluate Response To Treatment and Relapse Multiple Myeloma How to Evaluate Response To Treatment and Relapse D R L. G AR D E R E T Saint Antoine Hospital, Paris Haematology Department 1 What is Multiple Myeloma? 4 Diagnostic Tools 8 Response to

More information

Clinical Research Program Information for Patients. Transplant Creations

Clinical Research Program Information for Patients. Transplant Creations Clinical Research Program Information for Patients Transplant Creations 1 Program Focus Combination chemotherapy and transplantation of stem cells from an autologous donor (patient s own stem cells) and/or

More information

Pro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany

Pro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured

More information

Interim Results from a Phase 1/2 Clinical Trial of IMO-8400 in Waldenstrӧm s Macroglobulinemia

Interim Results from a Phase 1/2 Clinical Trial of IMO-8400 in Waldenstrӧm s Macroglobulinemia Interim Results from a Phase 1/2 Clinical Trial of IMO-8400 in Waldenstrӧm s Macroglobulinemia Presented at the American Society of Hematology 2015 Annual Meeting December 5, 2015 Toll-like receptor antagonism

More information

Bendamustine for the fourth-line treatment of multiple myeloma

Bendamustine for the fourth-line treatment of multiple myeloma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard

More information

Novel treatment Approaches of advanced stage Hodgkin Lymphoma

Novel treatment Approaches of advanced stage Hodgkin Lymphoma Novel treatment Approaches of advanced stage Hodgkin Lymphoma Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan Kettering Cancer Center 1992 (Cell): Durkop and Stein: Molecular cloning of CD30 =

More information

National Institute for Health and Care Excellence. Single Technology Appraisal (STA)

National Institute for Health and Care Excellence. Single Technology Appraisal (STA) National Institute for Health and Care Excellence Single Technology Appraisal (STA) Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib

More information

Initial treatment for myeloma

Initial treatment for myeloma Initial treatment for myeloma Dr Mamta Garg Consultant Haematologist Leicester Royal Infirmary At presentation 15% patients have no symptoms 38% emergency presentation - Kidney failure - Spinal cord compression/loss

More information

Immunomodulatory drugs in the treatment of Multiple Myeloma: focus on maintenance treatment. Pr Philippe Moreau University Hospital, Nantes, France

Immunomodulatory drugs in the treatment of Multiple Myeloma: focus on maintenance treatment. Pr Philippe Moreau University Hospital, Nantes, France Immunomodulatory drugs in the treatment of Multiple Myeloma: focus on maintenance treatment Pr Philippe Moreau University Hospital, Nantes, France Maintenance therapy is applied for a prolonged period

More information

M-protein in multiple myeloma

M-protein in multiple myeloma M-protein in multiple myeloma Plasma cells produce immunoglobulins (also called gammaglobulins), which consist of a heavy chain (IgG, IgA, IgM, IgD or IgE) and a light chain (kappa or lambda) linked together.

More information

Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.

Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Health Disparities in Multiple Myeloma Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Multiple Myeloma Overview Multiple myeloma (MM) is a type of blood cancer that develops

More information

PROTOCOL SYNOPSIS BMT CTN 1401 PROTOCOL

PROTOCOL SYNOPSIS BMT CTN 1401 PROTOCOL PROTOCOL SYNOPSIS BMT CTN 1401 PROTOCOL Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination

More information

Serum Free Light Chain Assays. The Binding Site, Inc. San Diego, CA

Serum Free Light Chain Assays. The Binding Site, Inc. San Diego, CA Understanding Serum Free Light Chain Assays Karen H van Hoeven MD Karen H. van Hoeven, MD The Binding Site, Inc. San Diego, CA Why Understand d Lab Test Results? Diabetes: blood sugar Heart disease: cholesterol

More information

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE

More information

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated

More information

Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients

Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients MQ. Lacy, S. Kumar, B. LaPlant, K. Laumann, M.Gertz, S. Hayman,

More information

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous

More information

Advancements in Science. Future strategies for myeloma: new insights and treatments in development

Advancements in Science. Future strategies for myeloma: new insights and treatments in development Advancements in Science Future strategies for myeloma: new insights and treatments in development Dr Matthew Jenner Consultant Haematologist University Hospital Southampton NHS Foundation Trust 1 This

More information

Treatment results with Bortezomib in multiple myeloma

Treatment results with Bortezomib in multiple myeloma Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of

More information

Multiple Myeloma Patient s Booklet

Multiple Myeloma Patient s Booklet 1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Email : ncis@nuhs.edu.sg Website : www.ncis.com.sg LIKE US ON FACEBOOK www.facebook.com/ nationaluniversitycancerinstitutesingapore Multiple

More information

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN + IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start

More information

Multiple Myeloma Workshop- Tandem 2014

Multiple Myeloma Workshop- Tandem 2014 Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone

More information

Outline of thesis and future perspectives.

Outline of thesis and future perspectives. Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy

More information

Statistical Center Update. Phyllis Goodman, M.S. Coordinating Statistician

Statistical Center Update. Phyllis Goodman, M.S. Coordinating Statistician Statistical Center Update Phyllis Goodman, M.S. Coordinating Statistician 2 Specimen labels Updated to reflect 3 types of specimen needs Large labels pathology specimens Small labels blood products, urine

More information

Future strategies for myeloma: An overview of novel treatments In development

Future strategies for myeloma: An overview of novel treatments In development Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide

More information

Efficacy. Table 1. Overall Objective Response. Day 1 Day 2 Day 3 Day 4...Days 5-28. (vincristine infusion) (doxorubicin infusion)

Efficacy. Table 1. Overall Objective Response. Day 1 Day 2 Day 3 Day 4...Days 5-28. (vincristine infusion) (doxorubicin infusion) COST EFFECTIVENESS OF VS IN NEWLY DIAGNOSED MULTIPLE MYELOMA Mohamad A. Hussein, MD, 1 Mark Wildgust, PhD, 2 John Fastenau, MPH, RPh, 3 Catherine Tak Piech, MBA, 3 and the C2000-003 Study Group 1 The Cleveland

More information

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Clinical Development Program Prof. Moshe Phillip, MD VP Clinical & Medical Affairs 1 Rationale for BL-8040 Development

More information

Current Multiple Myeloma Trials in Europe

Current Multiple Myeloma Trials in Europe Current Multiple Myeloma Trials in Europe Prof. Dr. Orhan Sezer Hamburg University Medical Center Optimising HDCT + ASCT Induction Bortezomib-Dex Vel-Cyclo-Dex Vel-ADM-Dex Vel-Thal-Dex Thal-Dex Thal-Cyclo-Dex

More information

Myeloma: A Guide for Patients and Caregivers

Myeloma: A Guide for Patients and Caregivers Myeloma: A Guide for Patients and Caregivers Printing of this publication made possible by a contribution from Myeloma is a type of cancer. There is no cure for myeloma. Still, this is a hopeful time for

More information

This talk will cover.

This talk will cover. Treatment for relapsed and/or refractory myeloma Dr Robin Aitchison Consultant Haematologist Buckinghamshire Heathcare NHS Trust This talk will cover. What do the terms 'relapsed myeloma' and 'refractory

More information

Multiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida

Multiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma: Novel Agents Robert A. Kyle, M.D. Germany June 28, 2008 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma Untreated Initial Therapy Transplant eligible Multiple

More information

Personalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease

Personalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease /publications/targeted-therapy-news/2012/november-2012/personalized-targeted-treatment-options- Offer-Hope-of-Multiple-Myeloma-as-a-Chronic-Disease Personalized, Targeted Treatment Options Offer Hope of

More information

Background Information Myeloma

Background Information Myeloma Myeloma FAST FACTS Myeloma, also known as multiple myeloma, is a type of cancer that develops from plasma cells which originate in the bone marrow 1 Myeloma is the second most common type of blood cancer

More information

National Myeloma Day Your Immune System and Medications. Julie Adams Managing Director and Clinical Pharmacist May 2016

National Myeloma Day Your Immune System and Medications. Julie Adams Managing Director and Clinical Pharmacist May 2016 National Myeloma Day Your Immune System and Medications Julie Adams Managing Director and Clinical Pharmacist Chemo@home May 2016 Talk Outline Treatment, highlighting new agents Patients suitable for

More information

Approaches to the Patient with Double-Refractory Myeloma Robert Z. Orlowski, Ph.D., M.D.

Approaches to the Patient with Double-Refractory Myeloma Robert Z. Orlowski, Ph.D., M.D. Approaches to the Patient with Double-Refractory Myeloma Robert Z. Orlowski, Ph.D., M.D. Florence Maude Thomas Cancer Research Professor Departments of Lymphoma/Myeloma & Experimental Therapeutics Principal

More information

Clinical Trials. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow

Clinical Trials. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow Multiple Myeloma Cancer of the Bone Marrow Understanding Clinical Trials 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 (worldwide)

More information

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart

More information

The Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma

The Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Webinar 3, September 17, 2015 Engineering the Immune System to Recognize Myeloma Cells Speakers Moderator: David Avigan, MD Harvard

More information

12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma

12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma 12. November 2013 Jan Endell From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma The MorphoSys Pipeline 21 Clinical Programs, 82 Total Program

More information

Newsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:

Newsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective: Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report

More information

Welcome and Introductions

Welcome and Introductions Clinical Trials or Standard Treatment? Understanding Options for Blood Cancers Welcome and Introductions Clinical Trials or Standard Treatment? Understanding Options for Blood Cancers John P. Leonard,

More information

NATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

NATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma NATIONAL CANCER INSTITUTE Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Basic Trial Information Phase Type Status Age Sponsor Protocol IDs Phase

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

POEMS syndrome. Myeloma Infosheet Series. Other related conditions. Infoline:

POEMS syndrome. Myeloma Infosheet Series. Other related conditions. Infoline: POEMS syndrome This Infosheet explains what POEMS is, what might cause it, what the symptoms are, how it is diagnosed and how it is treated and managed. What is POEMS syndrome? POEMS syndrome is a rare

More information

Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological

Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly

More information

Treatment of high-grade non-hodgkin lymphoma

Treatment of high-grade non-hodgkin lymphoma Produced 28.02.2011 Due for revision 28.02.2013 Treatment of high-grade non-hodgkin lymphoma Lymphomas are described as high grade if the cells appear to be dividing quickly. High-grade non-hodgkin lymphoma

More information

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black

More information

Smouldering myeloma. Myeloma Infosheet Series. Other related conditions Infoline:

Smouldering myeloma. Myeloma Infosheet Series. Other related conditions Infoline: Smouldering myeloma This Infosheet provides information on what smouldering myeloma is, how it is diagnosed, what the treatment is and will explain the link between smouldering myeloma and active myeloma.

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

MULTIPLE MYELOMA Treatment Overview

MULTIPLE MYELOMA Treatment Overview MULTIPLE MYELOMA Treatment Overview ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate

More information

Therapie des Patienten mit rezidiviertem Multiplem Myelom

Therapie des Patienten mit rezidiviertem Multiplem Myelom DGHO 2014, Hamburg Therapie des Patienten mit rezidiviertem Multiplem Myelom Martin Gramatzki Division for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University of Kiel, Kiel,

More information

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use

More information

Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma.

Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma. Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma. The intent is to positively identify patients with active or

More information

New Treatments in Multiple Myeloma ASS-FDA SYMPOSIUM 2015

New Treatments in Multiple Myeloma ASS-FDA SYMPOSIUM 2015 New Treatments in Multiple Myeloma ASS-FDA SYMPOSIUM 2015 S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine

More information

POM is a distinct oral immunomodulatory agent whose MOA consists of 3 primary effects 1 :

POM is a distinct oral immunomodulatory agent whose MOA consists of 3 primary effects 1 : MM-005: A Phase 1, Multicenter, Open-Label, Dose- Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients With Relapsed

More information

In ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior

In ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior - First and only immunostimulatory antibody approved in the European Union for multiple myeloma - Accelerated assessment and approval based on long-term data from ELOQUENT-2, which evaluated Empliciti

More information

DARA. 16 mg/kg IV (ARM B ONLY) Bortezomib SC 1.3 mg/m 2 D4 D2. Dexamethasone PO Total dose = 80 mg weekly. Figure 3. Castor treatment schedule.

DARA. 16 mg/kg IV (ARM B ONLY) Bortezomib SC 1.3 mg/m 2 D4 D2. Dexamethasone PO Total dose = 80 mg weekly. Figure 3. Castor treatment schedule. TPS8608 Twin Randomized Studies of Daratumumab () Plus Standard of Care (Lenalidomide/ Dexamethasone or Bortezomib/Dexamethasone [DRd or DVd]) Versus Rd or Vd Alone in Relapsed or Refractory Multiple Myeloma

More information

Understanding Serum Free Light Chain (Freelite ) Assays. Judith A. Finlay Ph.D. Director of Scientific Affairs The Binding Site, Inc.

Understanding Serum Free Light Chain (Freelite ) Assays. Judith A. Finlay Ph.D. Director of Scientific Affairs The Binding Site, Inc. Understanding Serum Free Light Chain (Freelite ) Assays Judith A. Finlay Ph.D. Director of Scientific Affairs The Binding Site, Inc. San Diego, CA Outline Background Tests used to Assess Multiple Myeloma

More information

Multiple myeloma maintenance therapy: A review of the pharmacologic treatment

Multiple myeloma maintenance therapy: A review of the pharmacologic treatment Review Article Multiple myeloma maintenance therapy: A review of the pharmacologic treatment Journal of Oncology Pharmacy Practice J Oncol Pharm Practice 2015, Vol. 21(1) 36 51! The Author(s) 2014 Reprints

More information

CAR T cell therapy for lymphomas

CAR T cell therapy for lymphomas CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What

More information

Cure versus control: Which is the best strategy?

Cure versus control: Which is the best strategy? Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control

More information

Mantle cell lymphoma. What is lymphoma? What kinds of lymphoma are there?

Mantle cell lymphoma. What is lymphoma? What kinds of lymphoma are there? Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk Mantle cell lymphoma Mantle cell lymphoma (MCL) is a rare form of lymphoma, accounting for approximately 1 in 20 of all

More information

Protocol Abstract and Schema

Protocol Abstract and Schema Protocol Abstract and Schema A Phase I, Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients with Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Description:

More information

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular

More information

Information Pathway. Intensive treatment autologous stem cell transplant. The principle behind stem cell transplantation. What are stem cells?

Information Pathway. Intensive treatment autologous stem cell transplant. The principle behind stem cell transplantation. What are stem cells? Information Pathway Myeloma UK Broughton House 31 Dunedin Street Edinburgh EH7 4JG Tel: + 44 (0) 131 557 3332 Fax: + 44 (0) 131 557 9785 Myeloma Infoline 0800 980 3332 www.myeloma.org.uk Charity No. SC

More information

Harry C Schouten MD PhD Maastricht University Medical Center

Harry C Schouten MD PhD Maastricht University Medical Center EBMT LWP TRAINING COURSE aggressive lymphomas New Options and Role of Autologous Stem Cell Transplantation Harry C Schouten MD PhD Maastricht University Medical Center September 2015 Heidelberg DISCLOSURES

More information

Chapter 2. S. Hovenga 1, J.Th.M. de Wolf 1, J.E.J. Guikema 4, H. Klip 2, J.W. Smit 3, C.Th. Smit Sibinga 5, N.A. Bos 4, E.

Chapter 2. S. Hovenga 1, J.Th.M. de Wolf 1, J.E.J. Guikema 4, H. Klip 2, J.W. Smit 3, C.Th. Smit Sibinga 5, N.A. Bos 4, E. Chapter 2 Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses; a high incidence of oligoclonal serum immunoglobulins post transplantation S. Hovenga, J.Th.M. de Wolf, J.E.J.

More information

It can be devastating to be diagnosed with a cancer like multiple myeloma. But there are treatments that can help you live longer and feel better.

It can be devastating to be diagnosed with a cancer like multiple myeloma. But there are treatments that can help you live longer and feel better. Patient information from the BMJ Group It can be devastating to be diagnosed with a cancer like multiple myeloma. But there are treatments that can help you live longer and feel better. What is multiple

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies

More information

Understanding the Immune System in Myeloma

Understanding the Immune System in Myeloma Brian GM Durie Understanding the Immune System in Myeloma Living Well with Myeloma Teleconference Series Thursday, March 19 th 2015 1 The Immune System is Like a Swiss Watch B Cell T Cell Plasma Cell Changing

More information

I've Just Been Diagnosed. with Multiple Myeloma, What s Next?

I've Just Been Diagnosed. with Multiple Myeloma, What s Next? I've Just Been Diagnosed with Multiple Myeloma, What s Next? Table of Contents Message from a Survivor Introduction What is Multiple Myeloma? What Causes Multiple Myeloma? Genes & Multiple Myeloma What

More information

Acute GVHD: Grading and Endpoints

Acute GVHD: Grading and Endpoints Acute GVHD: Grading and Endpoints Paul Martin, MD Fred Hutchinson Cancer Research Center, Seattle, WA Disclosures Contract support for clinical trials Osiris: Mesenchymal stem cells for secondary treatment

More information

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

More information

REVLIMID. Multiple Myeloma. Understanding. (lenalidomide) Improving Lives Finding the Cure. Cancer of the Bone Marrow

REVLIMID. Multiple Myeloma. Understanding. (lenalidomide) Improving Lives Finding the Cure. Cancer of the Bone Marrow Understanding REVLIMID (lenalidomide) A Publication of the International Myeloma Foundation Dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure. Multiple

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013

pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013 pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended

More information

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood [Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,

More information

MULTIPLE MYELOMA. Overview

MULTIPLE MYELOMA. Overview MULTIPLE MYELOMA Overview Steven R. Schuster, M.D. May 7, 2015 Objectives Give an overview of Multiple Myeloma Everything I know in 15 minutes Explain how genetic information can be used to personalize

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name BEZ235 Therapeutic Area of Trial Breast Cancer Approved Indication Investigational Protocol Number CBEZ235B2203

More information

Living Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern

Living Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

Leukemia and Lymphoma Overview

Leukemia and Lymphoma Overview Leukemia and Lymphoma Overview Michael Perry, M.D., M.S., M.A.C.P. University of Missouri/Ellis Fischel Cancer Center CALGB CRA Orientation, April 2008 For CALGB Participants Only Slide 1 Topics Acute

More information

ORIGINAL ARTICLE. European Journal of Haematology ISSN 0902-4441

ORIGINAL ARTICLE. European Journal of Haematology ISSN 0902-4441 European Journal of Haematology ISSN 0902-4441 ORIGINAL ARTICLE Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory

More information

Is FCR the standard d therapy for older cancer patients with chronic lymphocytic

Is FCR the standard d therapy for older cancer patients with chronic lymphocytic Is FCR the standard d therapy for older cancer patients with chronic lymphocytic leukemia? Véronique LEBLOND Hôpital PITIE-SALPETRIERE PARIS FRANCE How to treat chronic lymphocytic y leukaemia? FCR Fludarabine:

More information

Understanding Revlimid

Understanding Revlimid Understanding Revlimid International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454 TheIMF@myeloma.org

More information